{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-161662","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.728183+00:00","generated_at":"2026-06-01T04:21:48.104308+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mereo BioPharma prices $50M registered direct offering of 12.5M ADS at $3.99/ADS","bullets":["Gross proceeds $50M from 12,531,300 ADS at $3.99 each; net proceeds ~$45.9M after expenses.","Underwriters: Jefferies, Leerink Partners, and Cantor Fitzgerald acting as joint book-runners.","New investors include Frazier Life Sciences, Deerfield Management, and Perceptive Advisors; existing holder participation.","Net proceeds to fund setrusumab program (supply and pre-launch in Europe) and general corporate purposes.","Offering expected to close on June 17, 2024, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-161662","json":"https://secwatch.observer/filing/0001193125-24-161662.json","markdown":"https://secwatch.observer/filing/0001193125-24-161662.md","text":"https://secwatch.observer/filing/0001193125-24-161662.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524161662/0001193125-24-161662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312524161662/d828399d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:21:48.104308+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}